赣南医科大学学报2025，Vol.45Issue(1)：18-24,57,8.DOI:10.3969/j.issn.1001-5779.2025.01.003
嵌合抗原受体细胞工程技术在肿瘤治疗中的研究进展
Research progress of CAR cell engineering technology in tumor therapy
侯鉴基 1招冠钰 1孙阳 1黄英荷 1左勇1
作者信息
- 1. 广东医科大学海洋医药研究院,广东 湛江 524023
- 折叠
摘要
Abstract
Chimeric antigen receptor(CAR)mediated cellular immunotherapy is a new type of anti-tumor precision targeted therapy,which can achieve efficient targeted killing of tumor cells.CAR immunocell therapy is a hot research topic at present,in which CAR-T cells have made a major breakthrough in the treatment of B-cell line malignant hematological diseases,but have not been deeply studied in the treatment of solid tumors.In this paper,the current research achievements,limitations and optimization strategies of CAR cell immunotherapy were reviewed based on the literature at home and abroad in recent years.The results of the literature review showed that compared with CAR-T cells and CAR-natural killer cells,CAR-macrophages and CAR-neutrophils had enhanced killing ability on solid tumor cells and reduced adverse reactions during treatment.In the present study,it was found that the design of CAR structure and the source of CAR-mediated immune cells determined the targeting effect of CAR cells on tumor cells and the anti-tumor ability.It shows that CAR cell engineering technology is expected to play a significant role in the treatment of solid tumors through sufficient basic research and clinical experiments.关键词
嵌合抗原受体/CAR-T细胞/CAR-NK细胞/CAR-巨噬细胞/CAR-中性粒细胞Key words
Chimeric antigen receptors/CAR-T cells/CAR-NK cells/CAR-macrophages/CAR-neutrophils分类
临床医学引用本文复制引用
侯鉴基,招冠钰,孙阳,黄英荷,左勇..嵌合抗原受体细胞工程技术在肿瘤治疗中的研究进展[J].赣南医科大学学报,2025,45(1):18-24,57,8.
